Positive Results from Phase 3 PROMIS-I Study of CMS I-neb ® in Patients with Non-Cystic Fibrosis Bronchiectasis Presented at European Respiratory Society (ERS) Annual Meeting
Zambon, a pharmaceutical company on a mission to innovate cure & care to make patients’ lives better, is pleased to announce the final results from the Phase 3 PROMIS-I study, which were presented at the European Respiratory Society Congress today.
The study, which examined the use of CMS powder for nebulizer solution, delivered by the I-neb® AAD system (hereafter referred to as “CMS I-neb®”) for the prevention of pulmonary exacerbations in patients with NCFB, showed CMS I-neb® significantly reduced the annual rate of exacerbations and severe exacerbations in patients with NCFB and Pseudomonas aeruginosa chronic infection and prolonged the time to first exacerbation compared to placebo, also improving Quality of Life (QoL). The treatment was demonstrated to be well tolerated.
In patients with non-cystic fibrosis bronchiectasis, lung infection with P. aeruginosa is associated with frequent pulmonary exacerbations and admission to hospital for treatment, reduced quality of life, and increased mortality1. Currently there is no approved therapy for the disease.
The data were presented at the 9.30am CEST clinical trials session, ALERT: bronchiectasis and COVID’ under the abstract 31109/3979:The efficacy and safety of colistimethate sodium delivered via the I-neb® in bronchiectasis: the PROMIS-I randomized controlled trial.
The trial explored the effect of CMS I-neb® on the frequency of pulmonary exacerbations in NCFB patients chronically infected with P. aeruginosa. The trial met its primary endpoint, demonstrating that use of CMS I-neb® twice-daily resulted in a statistically significant reduction of pulmonary exacerbations over the course of the 12-month study. A total of 377 patients were randomized, 177 to CMS I-neb® and 200 to placebo. The annual rate of exacerbations was significantly lower in patients receiving CMS I-neb® vs placebo (0.58 per patient per year vs 0.95, rate ratio (RR) 0.61 95% CI 0.46-0.82, p=0.00101). The treatment effect was even larger in adherent subjects (43.5% reduction in exacerbations, p= 0.00080).
The trial also met important secondary endpoints, demonstrating improvements compared to placebo with prolonged time to first exacerbation in the CMS I-neb® group (HR 0.59, 95% CI 0.43-0.81, p=0.00074). The frequency of severe exacerbations was also reduced (RR 0.41 95% CI 0.23-0.74, p=0.00300). Quality of life measured by the St. George’s Respiratory Questionnaire (SGRQ) significantly improved in CMS I-neb® arm with 4.55 point difference vs placebo after 12 months treatment (p=0.0055). After 28 days treatment, P. aeruginosa density was significantly reduced in the treatment arm, p < 0.00001). The percentage of patients with adverse events was similar between groups. Bronchospasm and antibiotic resistance were infrequently observed (2.8% and 1% respectively).
“The PROMIS-I data show that CMS taken twice daily through the I-neb® reduces exacerbation frequency and improves quality of life in people with bronchiectasis and chronic P. aeruginosa infection,” said Dr. Charles Haworth, Respiratory Physician at the Cambridge Centre for Lung Infection at Royal Papworth Hospital, and PROMIS-I Chief Investigator. “The data also demonstrate that 12 months treatment is well tolerated. These results are encouraging for patients as there is currently no approved drug treatment for this indication.”
NCFB has a progressive course primarily determined by the rate of exacerbations, many of which are related to P. aeruginosa. Consequently, research efforts directed to treat infection by P. aeruginosa and its associated acute exacerbations remain a clinical priority2.
“We would like to extend our sincere gratitude to all of the patients and study centers for their collaboration throughout PROMIS-I,” said Paola Castellani, CMO and R&D Head at Zambon. “We are delighted to see that the hard work and commitment from all parties has paid off and provided us with encouraging data. We hope that these data will prove to be an important step as we seek a much-needed treatment to manage NCFB.”
The PROMIS clinical program has received FDA Qualified Infectious Disease Product (QIDP) and Fast Track designation for the prevention of pulmonary exacerbations in adult NCFB patients with P. aeruginosa.
“At Zambon, we are committed to developing treatments for severe respiratory diseases with limited treatment options,” said Roberto Tascione, CEO at Zambon. “This trial is testament to our growing credibility in this area, representative of our drive for innovation and creates a strong foundation upon which we can continue to grow and provide needed medicines to improve patients’ lives. With a number of our other mid- and late-stage trials in respiratory diseases ongoing, we are encouraged by the positive data of PROMIS-I which we hope is the first of many successes.”
There are no approved inhaled treatments currently available for patients with bronchiectasis and
P. aeruginosa infection; Zambon, together with its long-standing partner Xellia, will continue to actively work in strict collaboration, in order to make the drug approved across the globe.
- Finch S, McDonnell MJ, Abo-Leyah H, Aliberti S, Chalmers JD. A Comprehensive Analysis of the Impact of Pseudomonas aeruginosa Colonization on Prognosis in Adult Bronchiectasis. Ann Am Thorac Soc Vol 12, No 11, pp 1602–1611, Nov 2015
- Severiche-Bueno D, Gamboa E, Reyes LF, Chotirmall SH. Hot topics and current controversies in non-cystic fibrosis bronchiectasis. Breathe 2019; 15: 286–295
About the PROMIS-I Study
PROMIS-I is a double-blind, placebo-controlled, multi-centre, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled colistimethate sodium (CMS) in the treatment of subjects with non-cystic fibrosis bronchiectasis (NCFB) chronically infected with Pseudomonas aeruginosa. The study involved a total of 377 patient enrolled in the following 12 Countries: Australia, Belgium, Germany, Greece, Israel, Italy, Netherlands, New Zealand, Portugal, Spain, Switzerland, United Kingdom.
The primary objective of PROMIS-I trial was to investigate the effect on the frequency of pulmonary exacerbations of the use of inhaled CMS, administered twice daily via the I-neb® Adaptive Aerosol Delivery System for 12 months, compared to placebo in patients with non-cystic fibrosis bronchiectasis (NCFB) chronically infected with P. aeruginosa.
Secondary objectives included time to the first NCFB pulmonary exacerbation, number of severe NCFB pulmonary exacerbations, time to the first NFCB severe pulmonary exacerbation, quality of Life, P. aeruginosa density and resistance, number of exacerbation-free days, overall safety and tolerability.
Non-cystic fibrosis bronchiectasis (NCFB) is a chronic lung disease characterized by recurrent infection, inflammation, persistent cough, and production of sputum and its prevalence is increasing worldwide.
NCFB has a progressive course primarily determined by the rate of exacerbations, many of which are related to Pseudomonas aeruginosa. Consequently, research efforts directed to treat infection by P. aeruginosa and its associated acute exacerbations remain a clinical priority.
The objectives of treatment in bronchiectasis are to prevent exacerbations, reduce symptoms, improve quality of life and stop disease progression.
Cough and sputum production, along with breathlessness are the most frequent symptoms but rhinosinusitis, fatigue, hemoptysis and thoracic pain are also common.
The prevalence of NCFB varies among populations, with studies reporting an overall prevalence ranging from 486 to 1,106 per 100,000 persons, with higher prevalence being reported in females. Prevalence was also shown to increase with age and peaked at ages 80–84 years.
The incidence of NCFB appears to be rising too, particularly in women and older individuals.
About Colistimethate sodium (CMS)
Colistimethate sodium (CMS) is a pro-drug (the form used for inhalation therapy) of the antibiotic colistin.
Colistin is a polymyxin antibiotic derived from Bacillus polymyxa var. colistinus.
The polymyxin antibiotics are surface active agents and act by binding to and changing the permeability of the bacterial cell membrane, causing bacterial cell death.
Colistin is an active agent against aerobic Gram-negative pathogens that can cause life-threatening infections, an example being P. aeruginosa.
Colistin remains one of the few active antimicrobial agents against multi drug resistant Gram-negative bacteria and is currently considered one of the last therapeutic options for infections such as carbapenem-resistant P. aeruginosa.
The I-neb® is a third-generation nebulizer for Adaptive Aerosol Delivery (AAD).
The I-neb® is a small, battery powered, lightweight and silent drug delivery device, delivering a precise, reproducible dose of the drug.
The AAD technology ensures optimal drug delivery by only delivering medication when the patient inhales, (not continuously as in other nebulizers). This gives the medication the best opportunity to reach deep into the lungs and greatly reduces waste to the environment. AAD delivers the right amount of medication, regardless of breath size or breathing pattern.
I-neb® generates a fine-particle low-velocity aerosol, by forcing the liquid medication through a fine mesh. Faster than conventional jet or ultrasonic nebulizers, I-neb® support shorter treatment times (usually 3 to 4 minutes) and precise drug delivery.
About Zambon S.p.A.
Zambon is a pharmaceutical multinational company committed to innovating cure & care to improve patients’ lives. With ambitious plans for growth, its goal is to improve people’s health through the development of innovative and quality medicines.
Zambon products are commercialized in 87 countries. The company has 23 subsidiaries in three different continents – Europe, America and Asia – and owns manufacturing units in Italy, Switzerland, China and Brazil.
The company has taken now a new role in the industry On top of the diseases of the respiratory system, the urological system and Pain, Zambon is establishing a global pipeline and introducing important treatments for serious illness such as Parkinson’s Disease, Cystic Fibrosis, BOS and NCFB.
Zambon was established in 1906 in Italy and today counts around 2,398 employees all over the world.
For further information please visit www.zambon.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
FTI Consulting (media relations)
Ann Bartling/Sam Purewal
Tel. +44 20 3727 1000
Global Pharma Communication
Ph. +39 348 0404321
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
‘Hidden Gem’ Arrives in Rotterdam to be Transformed into Nodule Collection Vessel for The Metals Company21.9.2021 18:37:00 CEST | Press release
The Metals Company (Nasdaq: TMC) today announced that the 228-meter-long former drill ship renamed the Hidden Gem has arrived in Rotterdam, The Netherlands to begin its conversion into what is expected to be the first ship classified as a sub-sea mining vessel by the American Bureau of Shipping. TMC’s strategic partner Allseas acquired the former ultra-deep-water drill ship, which can accommodate 200 people, in March of 2020, as her configuration is well-suited for modifications that will enable the deployment at sea of a 4.5 kilometer-long riser to bring polymetallic nodules up from the seafloor. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005945/en/ Hidden Gem vessel (Photo: Business Wire) In partnership with The Metals Company (formerly DeepGreen Metals Inc.), Allseas is developing a deep-sea mineral collection system to responsibly recover polymetallic nodules from the ocean floor and transfer them to the surfac
Rhizen Pharmaceuticals AG Announces First Patient Dosed in a Phase 2 Study of RP7214 in Covid-19 Patients21.9.2021 18:36:00 CEST | Press release
Rhizen Pharmaceuticals AG, a clinical-stage oncology & inflammation-focussed biopharmaceutical company, today announced that the first patient has been dosed in a Phase 2 clinical trial of RP7214, a small molecule oral dihydroorotate dehydrogenase (DHODH) Inhibitor. The randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy & safety of oral RP7214, in covid-19 patients with mild, symptomatic disease with an underlying risk factor on the background of promising preclinical efficacy & phase 1 healthy volunteer safety. The study is being conducted in India across 12 centres in coordination with Rhizen’s India affiliate, Incozen Therapeutics Pvt ltd., and is designed to enrol up to 204 patients across both study arms. Viral replication involves a huge demand for building blocks and relies on nucleotides derived from host cells. DHODH is a rate-limiting enzyme in the pyrimidine biosynthesis pathway, inhibition of which leads to depletion of host nucleotide po
Citi Private Bank Finds Cautious Optimism Among Investors for 2022 with Covid-19, Inflation and Peak Market Valuations Top of Mind21.9.2021 18:31:00 CEST | Press release
Citi Private Bank’s Private Capital Group today released the results of its 2021 Family Office Survey, compiling the unique perspectives and insights of many of the world’s sophisticated family offices and ultra-high net worth investors in a challenging climate. This year’s survey included nearly 200 responses, an 11% increase from 2020. Four predominant themes emerged: 1) concern on rising inflation, 2) the prominence of high cash levels in the face of low yield environment, 3) continued growth in portfolio allocation to direct investing opportunities, and 4) a marked comeback in portfolio values year over year despite prevalent degree of macroeconomic uncertainty. While over three-fourths of all respondents seek returns of 5% or more over the next 12 months, the outlook is more optimistic for family offices with AUM over $500 million with 30% seeking over 10% returns versus 19% of family offices with AUM under $500 million. This likely factors in the additional institutional tools an
SSIMWAVE Selects Verimatrix Code Protection to Prevent Reverse Engineering of its Award-Winning Video Experience Platform21.9.2021 17:45:00 CEST | Press release
Regulatory News: Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced that Ontario, Canada-based SSIMWAVE Inc. is one of its latest customers to integrate Verimatrix Code Protection technology. IP theft is a growing threat to organizations worldwide. The Commission on the Theft of American Intellectual Property estimates that costs from IP losses are as high as $600 billion annually. “Verimatrix has a lengthy and successful history in the media and entertainment space, so it made sense to turn to their code protection technologies,” said Peter Olijnyk, Vice President of Engineering at SSIMWAVE. “When you’re protecting the core foundation of your platform, Verimatrix’s transparent and timely process for getting up and running – not to mention in about a day or so – was reassuring and provides peace of mind for SSIMWAVE and our customers.” A video quality innovator, SSIMWAVE evaluated numerous vendors and deci
Latest Report From Arthur D. Little Brings New Perspectives on Mobility-as-a-Service (MaaS)21.9.2021 17:22:00 CEST | Press release
Arthur D. Little (ADL) today released a new report on the current state of the global Mobility-as-a-Service (MaaS) market. Entitled ‘How To Realize The Promise Of Mobility-as-a-Service’, this study is released by the company’s Future Of Mobility Lab. While much has been written over the past few years about MaaS and its vision of revolutionizing transport in the modern city, much of the current discourse has been either academic or conceptual, envisaging ambitious futures built on fragile foundations. With this study, ADL aims to offer a more objective view of the subject, based on the company’s wide-ranging consultation with both public and private actors, and its assessment of the successes and failures of real world MaaS deployments. The study identifies five key factors for achieving a successful MaaS deployment. These are: Recognizing that MaaS is more than just an app, but should be part of a broader mobility vision requiring the development of integrated mobility policies, physi
project44 Buys Last-Mile Delivery and Customer Experience Leader, Convey, in $255M Acquisition21.9.2021 16:00:00 CEST | Press release
project44, the global leader in real-time supply chain visibility, today announced that it has acquired Austin-based Convey, the last-mile technology leader that powers exceptional direct-to-consumer delivery experiences for more than 200 of the world’s largest brands, including The Home Depot, Nieman Marcus, Ferguson, Ingram-Micro, and others. Convey, recognized as a Challenger in the Gartner 2021 Magic Quadrant for Real-Time Visibility Platforms, combines real-time visibility, post-purchase experiences, and machine learning-powered analytics to improve the overall customer experience. Together, the two companies now serve the global supply chain end-to-end, providing real-time visibility and actionable insights from raw materials to the front door to help brands deliver differentiated direct-to-consumer and eCommerce experiences for their customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005205/en/ project44
Andersen Global Continues Asian Expansion With Malaysian-Based Law Firm21.9.2021 15:30:00 CEST | Press release
Andersen Global continues its expansion in Asia through a Collaboration Agreement with Malaysian-based law firm Halim Hong & Quek Advocates & Solicitors (HHQ). Founded in 2000, HHQ offers full-service legal capabilities in alternative dispute resolution, banking and finance, corporate and M&A, energy and infrastructure, litigation, real estate and construction. With offices in Kuala Lumpur, Johor and Penang, the firm provides services to a wide range of domestic and international companies as well as high net worth individuals and foreign investors. “Our goal is to empower individuals and businesses with best-in-class legal services while creating a value-added social impact through our capabilities,” Managing Partner Dato’ Quek Ngee Meng. “We hire those who strive for the best and possess a positive mindset. Our team is dedicated to investing in our people to bring exceptional service and solutions to our clients. Collaborating with Andersen Global expands our platform and ability to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom